Evolus Strategic Advantage and Growth

LOVVOLUS JEUVEAU FASTEST-GROWING NEUROTOXIN IN THE U.S. FOR TWO CONSECUTIVE YEARS 11% #2 #1 OR 2 MARKET SHARE1 BRAND AWARENESS² NET REVENUE $255M- $265M** $202M* $148.6M $99.7M MARKET SHARE IN EVOLUS ACCOUNTS3 $56.5M $34.9M 2019 2020 2021 2022 2023 2024 1. 2. 3. Company estimates at year end 2022 Evolus Consumer Pulse Insights Survey Guidepoint Qsight Aesthetics Based on Preliminary Unaudited 2023 Results announced on January 16, 2024 ** Company guidance as of January 16, 2024 25

View entire presentation